Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development by Kiaie, Seyed Hossein et al.
Acta Pharmaceutica Sinica B 2021;11(5):1083e1097Chinese Pharmaceutical Association
Institute of Materia Medica, Chinese Academy of Medical Sciences
Acta Pharmaceutica Sinica B
www.elsevier.com/ loca te /apsb
www.sc iencedi rec t .comREVIEWImmune checkpoints in targeted-
immunotherapy of pancreatic cancer: New hope
for clinical developmentSeyed Hossein Kiaiea,b, Mohammad Javad Sanaeic,
Masoud Heshmatic, Zahra Asadzadeha, Iman Azimid, Saleh Hadidie,
Reza Jafarif,g, Behzad Baradarana,*aImmunology Research Center, Tabriz University of Medical Sciences, Tabriz 5173957616, Iran
bNano Drug Delivery Research Center, Kermanshah University of Medical Sciences, Kermanshah 6715847141,
Iran
cCellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical
Sciences, Shahrekord 8815713471, Iran
dSchool of Pharmacy and Pharmacology, College of Health and Medicine, University of Tasmania, Hobart 7001,
Tasmania, Australia
eClinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord University of Medical
Sciences, Shahrekord 8815713471, Iran
fSolid Tumor Research Center, Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences,
Urmia 5714783734, Iran
gDepartment of Immunology and Genetics, School of Medicine, Urmia University of Medical Sciences, Urmia










by Elorresponding author. Tel.: þ98 413 3
mail addresses: baradaranb@tbzmed
review under responsibility of Chine
//doi.org/10.1016/j.apsb.2020.12.011
3835 ª 2021 Chinese Pharmaceutic
sevier B.V. This is an open access aAbstract Immunotherapy has been recently considered as a promising alternative for cancer treatment.
Indeed, targeting of immune checkpoint (ICP) strategies have shown significant success in human malig-
nancies. However, despite remarkable success of cancer immunotherapy in pancreatic cancer (PCa),
many of the developed immunotherapy methods show poor therapeutic outcomes in PCa with no or
few effective treatment options thus far. In this process, immunosuppression in the tumor microenviron-
ment (TME) is found to be the main obstacle to the effectiveness of antitumor immune response induced
by an immunotherapy method. In this paper, the latest findings on the ICPs, which mediate immunosup-
pression in the TME have been reviewed. In addition, different approaches for targeting ICPs in the TME371440, fax: þ98 413 3371311.
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1084 Seyed Hossein Kiaie et al.of PCa have been discussed. This review has also synopsized the cutting-edge advances in the latest
studies to clinical applications of ICP-targeted therapy in PCa.
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In recent years, researchers have highlighted the importance of
pancreatic cancer (PCa) in its severity and generalizability. In the
past few decades, the concept of PCa has been faced with many
arguments in many aspects, however the general view toward the
PCa has been kept consistent, and PCa is still one of the most fatal
cancers in the world. Accordingly, PCa is defined as the disease in
which malignant cancer cells appear in the tissues of the pancreas1.
Pancreatic tumors are classified into exocrine or neuroendocrine
based on the cell from which they originate. This classification is
critical as it provides distinct functional characteristics and treat-
ment strategies between these two types. In theUnited States, PCa is
the 9th and 10th most frequently diagnosed cancer in females and
males, respectively2. Approximately 93% of PCa patients are
exocrine tumors. According to the American Cancer Society, PCa
patients account for approximately 3% of all adult cancer cases in
theUnited States, with only about 22%of exocrine PCa patients still
living one year after surgery. Above 56,000Americans are expected
to be diagnosed with PCa in 2019, with an average of above 150
diagnoses per day3. Recently, significant developments have been
made in cognizing the molecular biology, diagnosis, staging, and
treatment of PCa in patients4. As a turning point, cancer immuno-
therapy has emerged through monoclonal antibodies (mAbs) that
obstructs inhibitory receptors on immune-effector cells or their li-
gands on tumor cells and antigen-presenting cells (APCs) alleged
‘immune checkpoints’ (ICPs). The main ICPs that are expressed on
immune cells are programmed death 1 (PD-1), cytotoxic T-
lymphocyte-associated antigen 4 (CTLA-4), and lymphocyte-
activation gene 3 (LAG-3). The ligands of PD-1 (PD-L1 and PD-
L2), CTLA-4 (CD80 and CD86), and LAG-3 (MHC-II) could
bind to ICPs and trigger immunosuppression in the tumor micro-
environment (TME)5. This review is an attempt to focus on recent
advances as well as an outlook on targeting ICPs for attenuation or
elimination of PCa cells.
ICPs are regulatory molecules that maintain immune homeo-
stasis; however, they are overexpressed to suppress the anti-
tumoral immune response in the TME6. The immune system
plays a critical role in the elimination of tumor cells and fight
against cancer. It was demonstrated that the immune system un-
remittingly checks cells recognize any inappropriate and foreign
antigens such as tumor antigens. This process of inspection of the
immune system over the cells is called immune surveillance7.
One of the strategies used by tumors such as pancreatic ductal
adenocarcinoma (PDA) is to bypass the immune surveillance by
the misusage of ICPs to escape immune recognition8. It is in view
of this particular phenomenon that immunotherapy against ICPs
is expounded as a powerful strategy in the field of anti-cancer
therapy9, in which mAbs against PD-L1 and CTLA-4 were
established to be effective9e11. An immunosuppressive hallmark
of elevated expression of the ICP is the reduction of T cellsactivity12. B7-H1 or PD-L1 (CD274), as well as B7-DC and PD-
L2 (CD273), are ligands of PD-1 (CD279). PD-L1, PD-L2, and
PD-1 are transmembrane glycoprotein type I belong to the
immunoglobulin (Ig) superfamily B7 and CD28, respectively13.
The interaction between PD-1 on T cells and PD-L1 on APCs of
the TME and PCa cells promotes the suppression and exhaustion
of the T cells. Exhausted T cells have a significant role in leading
to a defective T cell reaction which weakens the tumor-specific
responses14. In PDA, CTLA-4, PD-1, and PD-L1 are three
major inhibitory checkpoints which are expressed in the TME15.
CTLA-4 (CD152) is a member of the Ig superfamily that binds to
CD28 on T cells and transmits an inhibitory signal to T cells16.
CTLA-4 has been first demonstrated as an inhibitory ICP mole-
cule, which can suppress T cells, as well as autoreactive T cells,
ordinary in lymph nodes16e18. Despite the mode of action of
CTLA-4, PD-1 influences T cells with its inhibitory role at late
stages of a T cell activity where PD-1 ligands are expressed. The
expression of PD-L1 on tumor cells and also myeloid-derived
suppressor cells (MDSC) in the TME could inhibit the activa-
tion of T cells5. A study showed that PD-L1 expression in PDA
cells enhanced cancer progression19. In addition to the direct
suppressive effects of the PD-1/PD-L1 axis on effector T cells,
studies have shown the role of this pathway in the induction of
regulatory T cells (Treg)
20. In vitro studies have indicated that the
presence of PD-L1 induces Treg activity
21,22. Furthermore, PD-1
inhibitors could hamper the induction of transforming growth
factor-b (TGF-b) and retinoic acid (RA)-induced Treg
23. It was
shown the elevated proportion of Treg for T CD8
þ cells led to
poor prognosis in cancers, suggesting that the induction of Treg is
one of the major approaches used by tumor cells to escape im-
mune surveillance24e26.
In PCa, the TME and the immune system show a vital role in
tumor growth. PCa features an extremely immunosuppressive
microenvironment, described by a dense desmoplastic stroma that
inhibits blood flow to the area, prevents delivery of drug, and stops
the antitumor immune reaction27. This supports cancer develop-
ment and metastasis through protecting pancreatic tumors from
immune surveillance. Moreover, the hypoxic milieu, acidic
extracellular pH, and high interstitial fluid pressure in the TME
also have a role in augmenting tumorigenesis28. Furthermore, the
PDA microenvironment is generally composed of Treg, MQs and
MDSCs, which stop the anti-tumoral function of effector CD4þ
and CD8þ T cells. Treg has been shown to play critical role in PDA
tumor development29. Tumor-associated macrophages (TAMs) are
also responsible for inflammation, development and metastasis of
PCa30. Upregulation of negative T cell co-stimulatory molecules
is another reason of stimulation of PDA immunosuppression31.
PD-L1 and PD-L2 are overexpressed in PDA patients and corre-
late with decreased tumor-infiltrating leukocytes (TILs) and a poor
prognosis. Therefore, PD-L1 downregulation prevents cell pro-
liferation in PCa32,33. In addition, an augmented expression of
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another strategy to stimulate immunosuppression of PCa34.
High CD8þ TIL correlates with a better prognosis due to their
cytotoxic functions in several types of solid tumors. The acqui-
sition of effector T cells (CD4þ and CD8þ) in human PCa can
improve overall survival (OS). Likewise, CD8þ effector T cells
reduce whereas suppressive Treg contain a higher CD4 T cell level,
which leads to a low number of TIL and a high number of
immunosuppressive cells35. PCa is poorly immune-responsive,
mainly due to its complex and suppressive TME. Therefore,
PCa requires combinational therapy to provoke an immune
response, for instance by employing vaccines to enhance the
accumulation of lymphoid aggregates36. Thus, TME, on account
of high levels of immunosuppression and poor immunogenicity,
provides a unique challenge in PCa immunotherapy36. The sig-
nificant milestones for the expression profile of immune cell and
ICPs in the TME are pointed out in Fig. 1.2. Immune checkpoint pathways
2.1. CTLA-4 pathway
Activation of T cells is a complex process and requires more than
one activating signal. Binding T cell receptor (TCR) to major
histocompatibility complex (MHC) is vital for T cell activation,
and other required costimulatory signals. In order to activate the
stimulatory signal in T cell, B7-2 (CD86) or B7-1 (CD80) mol-
ecules bind to CD28 molecules on the APCs. Adequate concen-
trations of CD28 for binding to B7 1/2 (CD80/CD86) leads to
generation of T cell with improved endurance, differentiation in
the enhanced cytokines structure like interleukin-2 (IL-2),
adjustment of durability of cell for genes and improved energy
metabolism. CTLA-4 delivers a negative regulatory signal to the T
cell through binding to B7 1/2 molecules. CTLA-4, a CD28 ho-
mologue, shows higher binding affinity to B737,38; however, the
binding of CTLA-4 to B7 withholds a stimulating signal through
CD28 reverse. The competition binding can block the stimulatory
signal generated by CD28eB7 binding38e40. Furthermore, the
corresponding quantity of CD28eB7 versus CTLA-4eB7 restrictsFigure 1 The expression profile of immune cells and ICPs in the
TME.the activation or energy of a T cell16. In addition, some data
suggest that CTLA-4eB7 can truly provide inhibitory signals
which prevent CD28eB7 and TCR:MHC binding stimulating
signals41,42. CTLA-4 location within the cell is under a controlled
mechanism and initially located in the intracellular segment of
resting naive T cells40,41,43. Consequently, the stimulatory signals,
including both TCR and CD28eB7 binding, trigger upregulation
of CTLA-4 through CTLA-4-included vesicles exocytosis on the
cell surface44, which explains how TCR signals extract high
translocation of CTLA-4 in a categorized feedback loop to the cell
surface. Whereas, inhibition of IL-2 production as well as stim-
ulation of the cell cycle progression has limited CTLA-4eB7
binding to fully activate of T cells45. Tregs regulate the effector T
cells’ activity and are indispensable to maintain peripheral toler-
ance46,47. Tregs constitutively express CTLA-4 unlike effector T
cell, thus, this is deemed crucial for their suppressive capabil-
ities46. In the animals, the absence of CTLA-4 on Treg impaired
their suppressive ability46,48. The downregulation of CD80 and
CD86 on APCs is one of Treg’s mechanisms to regulate the
function of effector T cells48,49.
2.2. PD-1 pathway
PD-1 as a part of the B7/CD28 costimulatory family regulates T
cell activation by binding to their ligands, PD-L1 and PD-L2.
Unlike CTLA-4, binding to PD-1 blocks the generation of stim-
ulating cytokines, such as tumor necrosis factor-a (TNF-a),
interferon-g (IFN-g) and IL-2, which lead to decrease in the ac-
tivity of T cells50. Where T cell activation coincides with
TCRePD-1 binding, the phosphorylation of intermediate TCR
signals is inhibited by PD-1 generated signals, which with ter-
minating TCR signals result in decrease T cell activation41,51.
Expression of PD-1 indicates “exhausted” T cells that practice
extreme rates of stimulation or reduced CD4þ T cell support52.
Dysfunction of T cell which is happening in the suboptimal
administration of tumors and some diseases, identifies this stage of
fatigue that occurs when chronic infections and cancer occur. Both
CTLA-4 and PD-1 receptors have proven negative effects on T
cell activation; however, the timing of downregulation, efficiency
of negative signaling pathway and the anatomical regions of in-
hibition are different17,50. While CTLA-4 utilizes T cell activation
in the priming state, PD-1 operates at the point of the effector,
predominantly within peripheral tissues50. For CTLA-4, the
combination of PD-1 ligands varies too. The B7 ligands for
CTLA-4 are expressed by special APCs that usually stay in the
lymph nodes or spleen, although PD-1 and PD-L2 are expressed in
T cell and, APC and more widely cancer cells, respec-
tively17,39,53,54. PD-L1 is expressed on leukocytes, non-
hematopoietic cells, non-lymphoid tissues as well as in paren-
chymal cells through tumorigenic signals or inflammatory cyto-
kines55. Expression of PD-L1 is differently identified in several
tumor types and is incorporated with the increase and decrease of
the amount of TILs and prognosis, respectively56e58. The
expression of PD-L2 is considerable in DCs and monocytes and
can be triggered depending on the microenvironment by a broad
range of particular immune and non-immune cells59. Binding af-
finity of PD-1 for PD-L2 compared to PD-L1 showed unique
tendency, which can be efficient for the differential immune
response involvement of the ligands60. The interactions of PD-1
with PD-L1 and PD-L2 are developed to make tolerance within
infiltrated tissue around due to PD-1 ligands are expressed in
peripheral tissues. One type of contradictory roles of PD-L1 and
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Th2 activity through restriction of PD-L2 binding points, although
CD80 binding to PD-L1 was provided to hinder T cell
responses61e63. The multiple biologic effects lead to differences in
the toxicity and activity for PD-1-directed antibodies which pre-
vent to bind both ligands as compared to interaction of PD-1 with
PD-L1. Despite Treg expression on both PD-1 and CTLA-4, the
purpose of PD-1 expression remains dubious. PD-L1 not only
provides Treg with the exchange of naive CD4
þ T cells, but also
prevents T cell responses by enhancing Treg induction and main-
tenance22. Similar to these results, the blockade of PD-1 is capable
of inverting the Treg-mediated defeat of the effector T cells
in vivo64. The immune response is reduced by PD-1 binding to its
ligands on T cells, which are busied on the effector T cell re-
sponses. This equal restriction of T cell activation, which is linked
to CTLA-4 blockade, may describe immune related adverse events
through the potentially inferior occurrence of PD-1, equivalent to
a CTLA-4 blockade52,65. Comparisons between CTLA-4 and
PD-1 demonstrate that they are both B7 receptor family
components66, expressed by activated T cells44,50, expression
affected by the strength and/or continuity of TCR signaling50,52,67,
decreased T cell proliferation, glucose metabolism, cytokine
manufacturing, durability and also arranging an extended T cell
proliferation17,39,50.
However, there are such differences include CTLA-4 expressed
through T cells, whereas PD-1 expressed through T cells and other
immune cells and further CTLA-4 first restricts T cell responses,
originally on lymphoid tissues, whereas PD-1 limits T cell
response anywhere usually. In peripheral tissues, PD-1 action
clashes with more T cell signaling mechanisms than CTLA-4 li-
gands expressed by professional antigen-presenting neurons. PD-
L1/2 expressed by APCs and other immune cells mostly, although
the ligands can be expressed on non-immune cells such tumor
cells. On the other hand, CTLA-4 inducing Treg functioning, thus,
the function of PD-1 on Treg is uncertain
17,39,48,50.3. Potential predictive biomarkers
3.1. CTLA-4
The structural similarity of CTLA-4 to CD28, let this inhibitory
checkpoint the ability to interact with CD80 and CD86 but in a
stronger affinity than CD2868. CTLA-4 can mediate the suppres-
sion of T cells through several mechanisms. First, CTLA-4 plays
an efficient role to reduce CD28 co-stimulation16,69, and its
interaction with CD80/86 of APCs can decrease APCs stimulatory
role in the T cells activation70. Second, expression of CTLA-4 on
Treg which gives them the ability to inhibit T cells function
71.
Third, inhibition of TCR genes and CD28-induced genes72,73.
Fourth, the expression of CTLA-4 in dendritic cells (DCs) that
inhibits T cells18.
In the case of PDA, it was shown that anti-CTLA-4 approach
did not provide an optimal clinical benefit and anti-tumor function
neither in human nor in cancer models74,75. However, a study
stated that there was an induction of the infiltration of CD4þ T
cells in the TME, as a result of anti-CTLA-4 approach, which has
no remarkable changes in the migration of CD8þ T cells75. This is
in total contrast with the approach of anti-CTLA-4 therapy for
melanoma patients, which showed a significant increase in infil-
tration of CD8þ T cells76. Thus, it can be suggested that CTLA-4
implicates the recruitment of CD4þ T cell in PDA patients. Likethese findings, Bengsch et al.75 exhibited that anti-CTLA-4 ther-
apy promotes T cell infiltration into the TME as well as T cell
activation. However, this approach was not clinically useful in
PDA patients. The interesting observation was the influence of
CD80 inhibition in the induction of T cell recruitment into the
TME. Consequently, the interaction of CTLA-4 and costimulatory
molecules (CD80/86) can regulate the migration of T cells to the
TME75. Basso et al.77 demonstrated that despite expression of
PD-L1 and CTLA-4 in splenic DCs, no PDA patients showed
increased levels of both PD-L1 and CTLA-4 expressions. They
observed that, for the first time, the S100A8/A9, also known as
calprotectin, could downregulate CTLA-4. Intriguingly, CTLA-4
negative DCs diminished T cell proliferation. DCs were also
shown to augment the inhibitory role of Treg in the inhibition of
allogeneic T cell responses through their CD8078. This is while
CD86 showed opposing function on the Treg activity
78.
3.2. PD-1
Activated monocytes, DC, NK, T and B cells express another
important ICP called PD-179. Like to CTLA-4, the responsibility
of PD-1 is to regulate T cell responses80. Domain-containing
phosphatase-1 and 2 (SHP-1&2) affiliated with immunoreceptor
tyrosine-based switch motif (ITSM) of PD-1 for stimulation
human T cell, whereas ligation of PD-1 inhibit T cell activa-
tion81,82. It was shown that CTLA-4 acts as an inhibitory molecule
in the primary phases of activation of T cells83 while the inter-
action of PD-1 and its ligands mainly happens on activated
effector T cells in the periphery5. In the TME of PDA, the PD-1
expression has predominantly happened in TILs, which leads to
immune escape by tumor cells13,84. However, recent research
presented PD-1 expression in PDA tumor cells85. It was demon-
strated that the amount of PD-1, which was expressed on CD8þ T
cells elevated in tumor tissue where this expression was signifi-
cantly correlated with the clinical stage of PDA patients. Indeed,
higher expression of PD-1 in PDA tumor tissue was considered as
a poor prognostic factor86. However, another investigation dis-
closed elevated stromal PD-1þTILs as a decisive prognostic
factor. In fact, they suggested a correlation between intraepithelial
and peripheral compartment of PD-1þTILs infiltration with better
progression-free survival (PFS) and distant metastases-free sur-
vival (DMFS)87. Nevertheless, investigations on a diversity of
cancers such as renal cell carcinoma (RCC), non-small cell lung
cancer (NSCLC), and melanoma demonstrated an enhanced PD-1
expression, which was affiliated with disease with poor
prognosis88e90. Thus, there is a controversy about the role of PD-1
as a satisfactory target for the targeted ICP therapy87. It was
demonstrated that PDA patients with elevated PD-1 expression
and dense stroma were associated with better OS91. Interestingly,
the stroma of PDA, is observed to have a role in the upsurge of
immune cell migration and accumulation, which led to a boosted
inflammatory response92. The expression of PD-1 in peripheral
blood stays stable even after surgical treatment and this stable
PD-1 level of peripheral CD8þ T cells was shown to be associated
with higher PDA recurrence86.
3.3. PD-L1
As conferred, PD-L1 is one of the inhibitory molecules
expressed in solid tumors, DCs and MQs of the TME93,94. It was
shown that PD-L1 from T gd cells of PDA could inhibit tumor-
specific cytotoxic T lymphocytes and Th1 cells95. Interesting
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have the ability to suppress T cells via binding to PD-114. In
general, the B7 family consists of PD-L1 (B7-H1) and PD-L2
(B7-H2)93. Although there is still a need for further studies to
understand the differences between the practical function of
PD-L1 and PD-L214, it was shown that PD-L1 is the primary
molecule that is presented in solid tumors13. PD-L1 can bind to
PD-1, CD80 of T cells, and APCs63. This binding leads to
apoptosis, energy exhaustion, and finally inhibition of effector T
cells13,96,97. In the case of PDA, PD-L1 was demonstrated to
have the ability to upregulate Treg infiltration and to induce
immune suppression20. The expression of PD-L1 in PDA was
shown to be associated with tumor growth, drug resistance, and
finally to high tumor invasion98. Another study in human PDA
showed that PD-L1 and PD-L2 were expressed in cancerous
pancreatic tissue. There was also a negative correlation between
PD-L1 expression and CD8þ T cells. Furthermore, 20 out of 51
PDA patients who were PD-L1 positive showed poor prog-
nosis99. The inhibition of blocking colony-stimulating factor 1
(CSF-1) and its receptor resulted in an increase in CD4þ/CD8þ
T cells infiltration and the expression of PD-L1100. Similarly,
high expression of HLA class I with PD-L1ePDA was indicated
to be associated with high CD8þ T cells infiltration and good
prognosis. It was suggested that the presence of HLA-I proba-
bility possess the potential to promote immunostimulatory
condition, whereas PD-L1 could induce the immunosuppressive
one. Thus, the immunological response of PDA pertains to the
balance of the TME between the two discussed conditions101.
Intriguingly, there was an association between the expression of
PD-L1, low tumor differentiation, and diminished advanced
tumor stage102. However, PD-L1 expression correlates with the
existence of immunosuppressive cells101.
It was shown that the remarkable function of PD-L1 happened
in the early stages of the disease99, while it was previously shown
that both PD-L1 and PD-L2 had their strong effect in the advanced
stages of esophageal cancer. This is while a correlation exists
between the expression of PD-L1 at high levels in PCa and the
metastasis of lymph node103. In another study, researchers re-
ported that there might be an association between miss match
repair (MMR) system deficient-cancer and the anti-PD-L1 treat-
ment. This is a result of the fact that this deficiency promotes the
production of multiple neo-antigens, which are further targeted by
the augmented immune system91.Figure 2 Pivotal ICPs in PCa and their interaction with specific
ligand. The interaction of negative ICPs, including PD-1, CTLA-4,
LAG-3, with their specific ligand were shown in detail. Interplay of
PD-L2 on the TME with B cells and NK cells and PD-L1 and CTLA-4
on the TME with T cell through their specific ligand activates the
immunosuppression and causes tumor immune evasion. Overex-
pressed LAG-3 on all of B cells, NK cells and T cell deactivates DC
and MQ functions which result in tumor-induced immunosuppression.4. Targeting immune checkpoints
Tumor cells can grow fast and spread in part by targeting the
immune system of the host. During the past decade, immuno-
therapy has emerged as an effective and standard method of
treating different cancers104. Even though, different treatment
strategies, such as surgery and conventional chemotherapies,
have prolonged patient survival and they do not inhibit restor-
ative. Consequently, new treatment strategies are indispens-
able105,106. Over the past decade, cancer immunotherapy has
paved the path from a promising preclinical use to a clinical
reality107. Manipulation of ICPs is one of the most current
promising strategies for cancer therapy35, therefore clinical
studies confirm that inhibition of ICPs disarranges adverse im-
mune regulations and induces immune system as well as anti-
tumor activities108. For this purpose, mAbs target inhibitory
ICPs and show significant results in different cancers109. Sincethey are accepted by the U.S. Food and Drug Administration
(FDA) and European Medicines Agency (EMA), ICP blockade
drugs have been developed for application to treat different
cancers109e114. Accordingly, it could also be a highly effective
therapy against PCa15. In this part, the latest advances and future
challenges of ICP inhibitors application in PCa are being sum-
marized. Pivotal ICPs in PCa and their interplay with their
specific ligands have been shown in Fig. 2.4.1. CTLA-4 immune checkpoint blockade
Recently, CTLA-4, the first clinically targeted ICP receptor, has
been studied extensively in cancer immunotherapy11,39,115. Ac-
cording to studies conducted in the late 90s, the opposing effect of
CD28 and CTLA-4 had demonstrated on T cell activation in vitro,
whereas blocking CD28 and CTLA-4 have declined and intensi-
fied anti-tumor responses, respectively116. Indeed, monotherapy-
based mice treated with anti-CTLA-4 antibodies led to the com-
plete tumor elimination and durable immunity. Subsequently,
mechanistic studies showed that this anti-tumor function was
related to the augmented ratio of both CD4 and CD8 effector cells
to FoxP3þ (forkhead box P3) Treg
117. Ipilimumab (Ipi) and
tremelimumab (Tre), two human anti-CTLA-4-antibodies, have
been applied clinically in PCa.
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Ipi, a fully humanized IgG1 kappa mAb, was the first drug
developed against CTLA-4118. In 2011, Ipi was approved by the
FDA to treat melanoma and is now under clinical evaluation in
various tumors119. Royal et al.120 investigated the effect of Ipi in
the regression of advanced pancreatic adenocarcinoma (APA)
during the phase II study. Twenty-seven people with APA received
3.0 mg intravenous Ipi, following which response evaluation
criteria in solid tumors (RECIST) and toxicity were measured.
This study found that the above mentioned dose-scheme of Ipi is
not effective in PCa and suggested the use of higher dosages of Ipi
at earlier stages of the disease, possibly with combinatorial
agents120. Granulocyte-macrophage colony-stimulating factor
(GM-CSF) of cell-based vaccines have been discovered to provide
a synergistic activity to anti-CTLA-4 antibodies. Therefore, in a
phase Ib of a study, Ipi has effectively been combined with GM-
CSF cell-based vaccines GVAX (a cancer vaccine containing
whole tumor cells which modified to secrete the immune stimu-
latory agents). In this study, thirty patients with PCa were listed
and Ipi (arm 1) and Ipi þ GVAX (arm 2) were examined121.
Following the administration, fifth patients indicated stable dis-
ease, and seven patients indicated CA19-9 reduction. An
enhancement in OS was detected that was related to the clinical
activity in the combination arm. In conclusion, this study showed
that checkpoint blockade plus GVAX is a potential candidate for
checkpoint immunotherapy, and requires assessment in larger
studies121. Kamath et al.122 tested a phase Ib clinical trial of
CTLA-4 inhibition with Ipi in combination with gemcitabine
(Gem) in patients with advanced PCa. This study established a
maximum tolerated dose for Gem and Ipi with a good overall
safety profile. Although the observed response rate was similar to
Gem alone, the durability of responses suggests a component of
immune activation that may warrant further investigation122.
Moreover, Parikh et al.123 conducted a phase II study of Ipi and
Niv with radiation in metastatic PCa. Dual blockade of CTLA-4
and PD-1 with radiation is feasible and reveals hopeful action in
these patients.
4.1.2. Tremelimumab
Tre is an anti-CTLA-4 mAb, which is assessed in melanoma,
colon cancer, gastric cancer, and mesothelioma in clinical trials124
possesses a greater affinity toward CTLA-4 than CD28. Ex vivo
studies of patient samples with expanded and metastatic mela-
noma disclosed that application of Tre decreases tumor develop-
ment via considerable stimulation of cytotoxic T cell activity125. A
phase I study in PCa patients, analyzed the tolerability, safety, and
maximum tolerated dose of Tre plus Gem. This combination
indicated a manageable safety and tolerability profile and pro-
longed OS126. A recent study investigated durvalumab (Dur) with
or without Tre for patients with metastatic PDA. Treatment was
well tolerated, and the efficiency of Dur plus Tre therapy and Dur
monotherapy presented a population of patients with mPDAC who
had poor prognoses and quickly developing disease127. Moreover,
a phase II study is testing Dur alone or Dur plus Tre in metastatic
PCa128. Furthermore, a study of hypofractionated radiotherapy in
combination with Dur and Tre in metastatic PCa patients is
underway129.
4.2. PD-1/PD-L1 immune checkpoint blockade
The second ICP receptor is PD-1, which appeared as a marker for
successful cancer immunotherapy39. It interacts with the PD-L1and PD-L2 ligands and stops T cell induction130. PD-1/PD-L1
axis enables tumor evasion from the immune responses, and this
interaction blockade with anti-PD-1 as well as anti-PD-L1 can
augment the tumor immunity. Moreover, the proliferation of
CD8þ T cell and production of cytokine can be induced by this
blockade131. Numerous PCa-related anti-PD-1 and anti-PD-L1
antibodies have been assessed in clinical trials. Nivolumab
(Niv), pembrolizumab (Pem), and pidilizumab (Pid) are the anti-
bodies that block PD-1. On the other hand, Dur and BMS-936559
are PD-L1 targeted antibodies132.4.2.1. Pembrolizumab
Pem (MK-3475) is a mAb of the IgG4k isotype considered to stop
PD-1 and PD-L1/2 interaction133. Recently, a phase I/IIa study is
analyzing the effect of colony-stimulating factor 1 receptor
(CSF1R) inhibitor (pexidartinib/PLX3397) and Pem combination
in PDA134. NCT02305186, another phase Ib/II study, assesses
safety and immunological effect of chemoradiation therapy (CRT)
plus Pem and CRT monotherapy in PCa patients135. Also,
NCT02362048 is ongoing to investigate the Bruton tyrosine ki-
nase (BTK) inhibitor, acalabrutinib, alone or with Pem for meta-
static PCa136. Furthermore, Mahalingam et al.137 reported that
reolysin (pelareorep), in combination with chemotherapy and
Pem, can be clinically successful and demonstrated convenient
safety profiles and anti-tumor function in metastatic PCa patients.
Furthermore, a study investigated Pem in combination with the
oncolytic virus pelareorep and chemotherapy in patients with
advanced PCa. Pelareorep in combination with chemotherapy and
Pem in these patients was well-tolerated and presented durable
efficacy. Further examination of pelareorep and anti-PD-1 therapy
is ongoing in follow-up studies138. A phase II study of PEGPH20
in combination with Pem for patients with hyaluronan (HA)-high
refractory metastatic PCa is ongoing. This research will examine
the efficacy, safety and translational biomarkers of PEGPH20 plus
Pem in these patients139. Moreover, Halama et al.140 tested
pharmacodynamic impact and safety of monotherapy with
CXCL12 inhibitor NOX-A12 plus Pem in PCa patients. These
patients with impaired immune systems and a high tumor load had
several unsuccessful prior lines of treatment. NOX-A12 plus Pem
showed induction of immune response, stabilize disease in 25% of
patients, and prolonged time on treatment versus prior therapy for
35% of patients140.4.2.2. Nivolumab
Niv is another therapeutic IgG4 antibody against PD-1 for
improving anti-tumor responses. In vitro assays showed that Niv
enhances T cell induction and cytokine production. Similar to
Pem, Niv stops PD-1 and its ligands interaction141. To evaluate the
effect of CY/GVAX and CRS-207 alone or in combination with
Niv, a phase II study is being directed in PDA patients who have
unsuccessful chemotherapy for metastatic disease142. Corre-
spondingly, an ongoing study by Firdaus et al.143 is studying nab-
paclitaxel and Niv plus Gem in advanced PCa patients. Presently,
Niv is being tested for safety and efficacy in phases I and II trials
for resectable (NCT02451982) and metastatic (NCT02423954)
PDA144. Wang-Gillam et al.145 are testing the effect of cabir-
alizumab (Cab) given with Niv with and without chemotherapy in
PCa patients. Also, a recent research is evaluating SD-101 (toll-
like receptor 9 agonist), Niv, and radiation therapy in treating
patients with chemotherapy-refractory metastatic PCa146.
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In recent years, Pid as another anti-PD-1 ICP inhibitor has
received consideration. It is a humanized IgG4k mAb. In PDA,
two clinical trials, were administered imperfectly, and stopped
thenceforth147,148.
4.2.4. Durvalumab
Dur is also another mAb of the IgG4k isotype which targets
PD-L1, stops the binding of PD-L1 to the PD-1 and CD80 mol-
ecules. In a recent study, Duffy et al.149 evaluated the impact of
combination therapy of radiation together with Tre and/or Dur in
PCa patients. This study showed that radiation could intensify the
impact of ICP stopping in these patients. Dur with or without Tre
in metastatic PCa patients was performed in phase II study129.
Additionally, a phase Ib/II study assesses the safety and efficacy of
Dur plus ibrutinib (BTK inhibitor) in PCa patients150. Currently, a
phase Ib study examined the combination of galunisertib (Gal) and
Dur in recurrent or refractory metastatic PCa. The combination of
Gal plus Dur had a suitable tolerability and safety profile. The
effect of this combination in second and third line PCa patients
warrants additional attention151. The study of Dur and stereotactic
radiotherapy in locally advanced PCa was safe, well tolerated and
appears to be clinically active with high rates of margin-negative
resection152. Cassier et al.153 performed a phase I dose escalation
research to assess the safety and clinical function of a combined
treatment relating an anti-CSF1R (pexidartinib) with Dur in pa-
tients with advanced/metastatic PCa. Toxicity was consistent with
the expected profiles of the individual drugs and no unpredicted
findings were observed with the combination.
4.2.5. Status of dMMR/MSI and PD1/PD-L1 and CTLA-4
antibodies
The mismatch repair (MMR) system plays an important role in
repair of DNA sequence during replication. Deficiency in the
MMR system (dMMR) or lack of performance of one of the
MMR proteins, including MLH1, MSH2, MSH6 and PMS2,
lead to an accumulation of somatic mutations, resulting in
microsatellite instability (MSI) and a higher neoantigen load
that enhances proinflammatory cytokines and activation of T
cells154. Given the recent tissue-agnostic approval of Pem, MSI
testing is now recommended by the National Comprehensive
Cancer Network (NCCN) for locally advanced or metastatic
PDA. A recent study of MMR status in PDA using next gen-
eration sequencing (NGS) revealed that dMMR occurs at a low
frequency of 0.8% in PDA, and all these cases also have Lynch
syndrome155. Furthermore, Yamamoto et al.156 and Macherla
et al.157 examined the prognostic impact of MSI in PCa cases
and found that MSI positives patients had longer survival time
than negative ones.
PD-L1 overexpression and dMMR/MSI status could indeed be
useful predictive biomarkers for the response to immunotherapy.
For this purpose, Kim et al.158 analyzed both PD-L1 and MLH1/
MSH2 expressions and showed a remarkable association between
PD-L1 expression and MLH1/MSH2 loss. Moreover, Salem
et al.159 studied the correlation between tumor mutational load
(TML), dMMR, and PD-L1 and found a lower frequency of TML-
high in PDA, and a positive PD-L1 expression in MSI-H and MSS
PDA cases at about 11.1% and 9%, respectively157,159. The ma-
jority of pancreatic adenocarcinoma patients with either MSI-H or
MSI-L showed low TML level. Future studies are needed to
indicate the suitability of PD-L1, MSI, and TML as appropriate
predictive markers of response to immunotherapy in PDAC157,160.Pem was recently evaluated in clinical trials in heavily pretreated
patients with MSI-H tumors161,162. Interestingly, these studies
demonstrated the benefit ICB in patients with MSI-H tumors
regardless of their PD-L1 status. Furthermore, Niv, as a PD-1
inhibitor, which is approved for progressed MSI-H/dMMR meta-
static colorectal cancer (CRC) following first-line treatment,
indicated that dMMR plays a robust predictive of response to ICB
in comparison to PD-L1157,163. Furthermore, the activated
V-domain immunoglobulin suppressor of T cell activation
(VISTA) which is expressed on the MQs pathway, decreases T cell
responses in the tumor at a greater rate compared to PD-L1
blockade. Therefore, PD-1/PD-L1 blockade might breakdown
PDA treatment due to suppression of the immune response
through an untreated VISTA pathway. Enhancement of T cell
infiltration, using anti-CTLA-4 mAb with anti-VISTA antibody to
target MQs as combination therapy, holds a promising new
strategy for PDA treatment164,165.
4.2.6. BMS-936559
BMS-936559, a humanized IgG4 and PD-L1-specific mAb, can
prevent the interaction of PD-L1 with both PD-1 and CD80. In
NSCLC, RCC and melanoma patients, durable tumor regression
and long-term disease stabilization were observed by PD-L1
blockade; however, in PCa, no objective response was
detected9,166.
4.3. LAG-3 immune checkpoint blockade
LAG-3 or CD223, a homolog of CD4, was cloned over 25 years
ago167. The negative regulatory role for LAG3eMHC-II interac-
tion is the most prominent characteristic of LAG-3, and this fact
represents LAG-3 as a potential treatment target168. In 2006, tar-
geted immunotherapy through LAG with a soluble LAG-3Ig
fusion protein (IMP321) was introduced. While, IMP321 was
used for three clinical trials in RCC, metastatic breast carcinoma,
and melanoma previously with average success. It is still being
tested in other novel clinical trials, where it may reveal additional
therapeutic advantages169e171. LAG-3 was shown to synergize
with PD-1 in downregulating T cell activities and stimulating
immune evasion by cancer cells. Even though, targeting of LAG-3
alone showed little effect, and blockade of LAG-3 has been
revealed to synergize with PD-L1 and augment its anti-tumor
effect172. These trials are investigating the application of combi-
nation anti-LAG-3 and anti-PD-1 versus anti-LAG-3 alone in
diverse solid tumors173. These results have received certain in-
terest in perspective, hence LAG-3 will be considered as the
promising targeted immunotherapy and predictive biomarker174.
Table 19,120e123,127,129,134e139,142e146,149e153,166,175,176 summa-
rizes the clinical trials of targeted ICPs in PCa.
5. In vitro studies of immune checkpoint blockade
The expression of PD-L1 protein is typically limited to MQ
lineage in human and it has the capacity to be induced in B cells,
tumor cells such as PCa, as well as other hematological cells, and
non-lymphatic tissues13,177. Furthermore, PD-L2 expression is
inducible for MQs and DCs178. A study was conducted in Panc-
02 cells, where they were directly injected into the pancreas. It
was shown that blocking antibodies against B7eH1 could sup-
press tumor growth179. Studies in the MiaPaCa-2 and
Su86.80 cell lines showed that the anti-inflammatory cytokines
Table 1 Clinical trials of targeted ICP in Pca.
Target Drug Phase Status Clinical Trials identifier Ref.
CTLA-4 Ipilimumab II Completed NCT00112580 120
Ipilimumab  GVAX I Completed NCT00836407 121
Ipilimumab þ GVAX II Recruiting NCT01896869 175
Ipilimumab þ gemcitabine Ib Completed NCT01473940 122
Ipilimumab þ nivolumab with radiation II Recruiting NCT03104439 123
Tremelimumab (CP-675,206) þ gemcitabine Ib Completed NCT00556023 128
Tremelimumab þ durvalumab II Completed NCT02558894 127
PD-1 Pembrolizumab þ REOLYSIN þ chemotherapy II Recruiting NCT02620423 137
Pembrolizumab þ ACP-196 II Active but not recruiting NCT02362048 136
Pembrolizumab (MK3475) I/II Recruiting NCT02305186 135
Pembrolizumab þ PLX3397 I Recruiting NCT02452424 134
Pembrolizumab þ oncolytic virus pelareorep Ib Recruiting NCT02620423 138
Pembrolizumab þ PEGPH20 II Recruiting NCT03634332 139
Pembrolizumab þ NOX-A12 II Completed NCT03168139 176
Nivolumab þ GVAX þ cyclophosphamide I/II Active but not recruiting NCT02451982 144
Nivolumab þ Nab-paclitaxel þ gemcitabine I Recruiting NCT02309177 143
Nivolumab þ GVAX þ CRS-207 II Recruiting NCT02243371 142
Nivolumab þ cabiralizumab þ chemotherapy II Active but not recruiting NCT03336216 145
Nivolumab þ SD-101 I Recruiting NCT04050085 146
PD-L1 BMS-936559 I Completed NCT00729664 9,166
Durvalumab þ ibrutinib mesylate Ib/II Recruiting NCT02403271 150
Durvalumab þ galunisertib 1 b Completed NCT02734160 151
Durvalumab þ stereotactic radiotherapy I/II Recruiting NCT03245541 152
Durvalumab þ pexidartinib I Completed NCT02777710 153
PD-L1, CTLA-4 Tremelimumab þ MEDI4736 I Recruiting NCT02311361 149
Durvalumab þ tremelimumab II Recruiting NCT02558894 129
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PD-L1 in PCa cells. In contrast, treatment with IFN-g upregu-
lated mRNA expression of PD-L120. Following hemi-spleen
implantation of tumor Panc-02 cells, which are treated with
cyclophosphamide (Cy) and GVAX or aPD-1/aPD-L1 therapy, it
showed elevated amounts of IFN-g secreted from CD8þ T cells
and tumor-specific CD8þ T cells in the TME. CD8þ T cells
isolated from spleen and TILs with tumor Panc-02 cells as
antigenic targets were treated with anti-PD-1,
Cy þ GVAX þ IgG, and Cy þ GVAX þ anti-PD-1, showing
enhanced amounts of IFN-g secreted from CD8þ T cells in in-
cremental order compared to the untreated cells180. A syngeneic
orthotopic tumor Panc-02 cells poorly responded for blockage of
PD-L1 and CTLA-4 as well as Gem, while CD40 agonist anti-
body (aCD40) treatment significantly delayed tumor growth and
increased survival. It also drove maturation of myeloid cells and
expansion of memory T cell in spleen and upregulated the PD-L1
mRNA expression in Pan-02 tumors. The combination of aCD40
with aPD-L1 resulted in a significant upsurge of OS rate
compared to either agent of the alone treatment trials181. Many
of the cancer studies have observed tumor cells via types I and
type II IFN signaling pathways upregulated PD-L1 expression in
human and murine PCa cell lines. In many studies, nivolumab on
PANC-1 cell182, ruxolitinib (JAKeSTAT pathway inhibitor) on
PANC-02-H7 cell183 and 5-fluorouracil, Gem or paclitaxel
(upregulate cell surface PD-L1 expression) on AsPC-1, MIA
PaCa-2 and Pan-02 cells184 have a significant influence in
downregulation of PD-1/PD-L1 protein levels on the surface of
tumor cells. The combined effect of these drugs and IFNs indi-
cated that PD-L1 is activated through the JAKeSTAT1 pathway
by both type I and II IFNs. It also uncovered that JAKeSTAT
pathway inhibition increases the effectiveness of anti-PD-1
immunotherapy to suppress the growth of PCa185. Both type Iand II interferon cytokines engage JAKeSTAT signaling path-
ways. The expression of PD-L1 is a primary limiting factor for
CTL activities in gastric cancers and is significantly upregulated
by IFN-g exposure184,186,187. Taken together, these findings
suggest that PD-1/PD-L1 might be a critical target for controlling
the growth of PCa.
CTLA-4 is homologous to the T-cell costimulatory protein
called CD28 and is constitutively expressed in Treg but is only
upregulated after activation in conventional T cells. It appears to
be particularly notable in cancers and acts as an “off” switch on
the surface of APCs once bounded to CD80 (B7-1) or CD86 (B7-
2)16,188,189.
LAG-3 which belongs to immunoglobulin (Ig) superfamily
is expressed on activated T cells, NK cells, B cells, and
plasmacytoid DCs. Although LAG-3 acts as target of different
drug development programs, it has diverse biological effects
on T cell functions167,190e193. The binding of LAG-3 to MHC
class II (its ligand) has a higher affinity than CD4 (immune
cell surface glycoprotein)194. LAG-3 helps to maintain the
tolerogenicity of CD8þ T cells and CD8 exhaustion during
chronic infection, contributing to the maturation as well as
activation of DCs, and like CTLA-4 and PD-1, it negatively
regulates proliferation, activation, and homeostasis of T
cells12,161,162,167,195, therefore plays a vital role in the sup-
pression of Treg function
168. Co-inhibitory molecules,
including IL-12 and TGF-b, which play the role of induction
and suppression of LAG-3 and PD-1, respectively, block ICPs
to reverse pathogenic Treg. In addition, the effects of co-
inhibitors on NK cells indicate different expression in
response to cytokine stimulations of IL-15 at least, demon-
strating the regulatory role of the co-inhibitors on human NK
cells. Furthermore, IL-15 can promote NK cell-mediated
killing in pancreatic stellate cells (PSC)196,197.
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siRNAs, a group of regulatory therapeutic factors, were rabidly
designed to combat various diseases, including cancer, neurode-
generative disorders, and infectious diseases198,199. The applica-
tion of siRNA in PCa to target immune checkpoints was studied in
some investigations. A recent study used a PD-L1-specific siRNA
conjugated to a magnetic nanocarrier (MN-siPDL1) in combina-
tion with gemcitabine as a therapeutic method in murine PCa
models. The strategy reduced the tumor growth and elevated the
survival ratio significantly. At 2 weeks from the beginning of the
treatment, a 90% tumor volume reduction was attained. This is
while 100% of the control group animals were observed with a
tumor by 6 weeks after starting the treatment200.
Although the failure of anticancer vaccines in PCa patients, a
multilateral effort to develop new vaccines demonstrates an effi-
cient efficacy in case survival. Several strategies have been
developed to improve the efficacy and safety of tumor vaccines.
These include single immunotherapy approaches such as breaking
immunosuppression within the tumor microenvironment and
overcoming tolerance to TAAs, as well as combinatorial immu-
notherapy approaches such as the combination of anticancer
vaccines with ICP inhibitors and chemotherapy, radiation therapy
or even surgery201,202. Recent findings suggest a multipronged
approach for therapeutic efficacy, including various types of
agents such as vaccines or oncolytic viruses and additional agents
to prime the immune microenvironment, followed by ICP in-
hibitors127. Despite the lack of an effective tumor vaccine, a dozen
more clinical trials are ongoing. For instance, use of heterologous
prime-boost followed by a low dose of Cy/GM-CSF gene-trans-
fected tumor cell (GVAX) and live-attenuated Listeria
monocytogenes-expressing mesothelin (CRS-207) has extended
patient survival with minimal toxicity through enhancement of
innate and adaptive immunity203.7. Conclusions and perspectives
The adverse effects caused by immunotherapy in the order of their
importance include neutropenia, nausea and vomiting, alopecia,
fatigue, and thrombocytopenia204. Despite of the adverse effects,
high levels of immunosuppression in the TME and poor immu-
nogenicity provide significant challenges to prosperous immuno-
therapy of human PCa. On the other hand, ICPs have been
discovered to perform an axial role in the establishment of tumor-
induced immunosuppression in the TME. Therefore, targeting of
ICPs is suggested to be a hopeful strategy for improving the
therapeutic efficacy of PCa immunotherapy. CTLA-4 and PD1/
PD-L1 are the most well-known ICPs that have been targeted
for overcoming immunosuppression in the TME and induction of
effective anticancer immune responses in PCa. The results of
clinical studies in patients showed the safety and superior thera-
peutic efficacy of combination therapy with anti-CTLA-4 and
anti-PD1 or anti-PD-L1 mAbs in PCa. Despite the encouraging
results, several clinical studies showed poor response to check-
point blockade with anti-CTLA-4 and anti-PD-1 or anti-PD-L1
immunotherapies in PCa patients due to resistance to CTLA-4
and PD-1/PD-L1-targeted therapies. The lack of significant clin-
ical response to PD-1 or CTLA-4-targeted therapy in PCa is
possibly due to the presence of unknown and new emerging ICPs
that may be involved in tumor-induced immunosuppression and
our incomplete understanding of the function of immune cells andmolecules in the TME. Our continued progress toward under-
standing the immunobiology and targeting of ICPs in this type of
human malignancy, as discussed in the present article, promises a
new hope in the treatment of PCa in the future.
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Hülsmeyer M, et al. An engineered lipocalin specific for CTLA-4
reveals a combining site with structural and conformational fea-
tures similar to antibodies. Proc Natl Acad Sci U S A 2009;106:
8198e203.
42. Haspot F, Villemain F, Laflamme G, Coulon F, Olive D, Tiollier J,
et al. Differential effect of CD28 versus B7 blockade on direct
pathway of allorecognition and self-restricted responses. Blood 2002;
99:2228e34.
43. Lu Y, Schneider H, Rudd CE. Murine regulatory T cells differ from
conventional T cells in resisting the CTLA-4 reversal of TCR stop-
signal. Blood 2012;120:4560e70.
44. Valk E, Rudd CE, Schneider H. CTLA-4 trafficking and surface
expression. Trends Immunol 2008;29:272e9.
45. Brunner-Weinzierl MC, Hoff H, Burmester GR. Multiple functions
for CD28 and cytotoxic T lymphocyte antigen-4 during different
phases of T cell responses: implications for arthritis and autoimmune
diseases. Arthritis Res Ther 2004;6:45e54.
46. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J,
Sakaguchi N, et al. Immunologic self-tolerance maintained by
CD25þCD4þ regulatory T cells constitutively expressing cytotoxic T
lymphocyte-associated antigen 4. J Exp Med 2000;192:303e10.
47. Piccirillo CA, Shevach EM. Naturally-occurring CD4þCD25þ
immunoregulatory T cells: central players in the arena of peripheral
tolerance. Semin Immunol 2004;16:81e8.
48. Noh MY, Lee WM, Lee SJ, Kim HY, Kim SH, Kim YS. Regulatory T
cells increase after treatment with poly (ADP-ribose) polymerase-1
inhibitor in ischemic stroke patients. Int Immunopharm 2018;60:
104e10.
49. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C,
Schmidt EM, et al. Trans-endocytosis of CD80 and CD86: a mo-
lecular basis for the cell-extrinsic function of CTLA-4. Science 2011;
332:600e3.
50. Brunner-Weinzierl MC, Rudd CE. CTLA-4 and PD-1 control of T-
cell motility and migration: implications for tumor immunotherapy.
Front Immunol 2018;9:2737.
51. Hsu H, Boudova S, Mvula G, Divala TH, Mungwira RG, Harman C,
et al. Prolonged PD1 expression on neonatal Vd2 lymphocytes
dampens proinflammatory responses: role of epigenetic regulation. J
Immunol 2016;197:1884e92.
52. Khan N, Vidyarthi A, Amir M, Mushtaq K, Agrewala JN. T-cell
exhaustion in tuberculosis: pitfalls and prospects. Crit Rev Microbiol
2017;43:133e41.
53. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation
immunotherapydinhibiting programmed death-ligand 1 and pro-
grammed death-1. Clin Cancer Res 2012;18:6580e7.
54. Umezu D, Okada N, Sakoda Y, Adachi K, Ojima T, Yamaue H, et al.
Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-
tumor immunity in murine tumor microenvironment. Cancer
Immunol Immunother 2019;68:201e11.
55. Podojil JR, Miller SD. Targeting the B7 family of co-stimulatory
molecules: successes and challenges. BioDrugs 2013;27:1e13.
Immune checkpoints in targeted-immunotherapy of pancreatic cancer 109356. Zhao Q, Hu F, Xiao Z, Li M, Wu X, Zhao Y, et al. Comprehensive
molecular profiling of the B7 family in gastrointestinal cancer. Cell
Prolif 2018;51:e12468.
57. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. As-
sociation of PD-1, PD-1 ligands, and other features of the tumor
immune microenvironment with response to anti-PD-1 therapy. Clin
Cancer Res 2014;20:5064e74.
58. Drakes ML, Mehrotra S, Aldulescu M, Potkul RK, Liu Y, Grisoli A,
et al. Stratification of ovarian tumor pathology by expression of
programmed cell death-1 (PD-1) and PD-ligand-1 (PD-L1) in ovarian
cancer. J Ovarian Res 2018;11:43.
59. Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ. Pro-
grammed death ligand 2 in cancer-induced immune suppression. Clin
Dev Immunol 2012;2012:656340.
60. Ritprajak P, Hashiguchi M, Akiba H, Yagita H, Okumura K,
Azuma M. Antibodies against B7-DC with differential binding
properties exert opposite effects. Hybridoma 2005;31:40e7. 2012.
61. Huber S, Hoffmann R, Muskens F, Voehringer D. Alternatively
activated macrophages inhibit T-cell proliferation by Stat6-dependent
expression of PD-L2. Blood 2010;116:3311e20.
62. Akbari O, Stock P, Singh AK, Lombardi V, Lee WL, Freeman GJ,
et al. PD-L1 and PD-L2 modulate airway inflammation and iNKT-
cell-dependent airway hyperreactivity in opposing directions.
Mucosal Immunol 2010;3:81e91.
63. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Pro-
grammed death-1 ligand 1 interacts specifically with the B7-1 cos-
timulatory molecule to inhibit T cell responses. Immunity 2007;27:
111e22.
64. Stewart R, Morrow M, Hammond SA, Mulgrew K, Marcus D,
Poon E, et al. Identification and characterization of MEDI4736, an
antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res
2015;3:1052e62.
65. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new
immunotherapeutic modalities with durable clinical benefit in mel-
anoma patients. Clin Cancer Res 2013;19:5300e9.
66. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited.
Annu Rev Immunol 2005;23:515e48.
67. Krishnadas DK, Wang Y, Sundaram K, Bai F, Lucas KG. Expansion
of cancer germline antigen-specific cytotoxic T lymphocytes for
immunotherapy. Tumour Biol 2017;39:1010428317701309.
68. Pentcheva-Hoang T, Egen JG, Wojnoonski K, Allison JP. B7-1 and
B7-2 selectively recruit CTLA-4 and CD28 to the immunological
synapse. Immunity 2004;21:401e13.
69. Masteller EL, Chuang E, Mullen AC, Reiner SL, Thompson CB.
Structural analysis of CTLA-4 function in vivo. J Immunol 2000;164:
5319e27.
70. Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. Foxp3þ natural
regulatory T cells preferentially form aggregates on dendritic cells
in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S
A 2008;105:10113e8.
71. Jain N, Nguyen H, Chambers C, Kang J. Dual function of CTLA-4 in
regulatory T cells and conventional T cells to prevent multiorgan
autoimmunity. Proc Natl Acad Sci U S A 2010;107:1524e8.
72. Riley JL, Mao M, Kobayashi S, Biery M, Burchard J, Cavet G, et al.
Modulation of TCR-induced transcriptional profiles by ligation of
CD28, ICOS, and CTLA-4 receptors. Proc Natl Acad Sci U S A 2002;
99:11790e5.
73. Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C,
Brewer JM, et al. Reversal of the TCR stop signal by CTLA-4.
Science 2006;313:1972e5.
74. Feig C, Jones JO, Kraman M, Wells RJB, Deonarine A, Chan DS,
et al. Targeting CXCL12 from FAP-expressing carcinoma-associated
fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic
cancer. Proc Natl Acad Sci U S A 2013;110:20212e7.
75. Bengsch F, Knoblock DM, Liu A, McAllister F, Beatty GL. CTLA-
4/CD80 pathway regulates T cell infiltration into pancreatic cancer.
Cancer Immunol Immunother 2017;66:1609e17.76. Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S,
et al. CTLA4 blockade induces frequent tumor infiltration by acti-
vated lymphocytes regardless of clinical responses in humans. Clin
Cancer Res 2011;17:4101e9.
77. Basso D, Fogar P, Falconi M, Fadi E, Sperti C, Frasson C, et al.
Pancreatic tumors and immature immunosuppressive myeloid cells
in blood and spleen: role of inhibitory co-stimulatory molecules
PDL1 and CTLA4. An in vivo and in vitro study. PLoS One 2013;8:
54824.
78. Zheng Y, Manzotti CN, Liu M, Burke F, Mead KI, Sansom DM.
CD86 and CD80 differentially modulate the suppressive function of
human regulatory T cells. J Immunol 2004;172:2778e84.
79. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in
tolerance and immunity. Annu Rev Immunol 2008;26:677e704.
80. Chen L. Co-inhibitory molecules of the B7-CD28 family in the
control of T-cell immunity. Nat Rev Immunol 2004;4:336e47.
81. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H,
et al. Engagement of the PD-1 immunoinhibitory receptor by a novel
B7 family member leads to negative regulation of lymphocyte acti-
vation. J Exp Med 2000;192:1027e34.
82. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and
SHP-2 associate with immunoreceptor tyrosine-based switch motif of
programmed death 1 upon primary human T cell stimulation, but
only receptor ligation prevents T cell activation. J Immunol 2004;
173:945e54.
83. Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-
inhibitory receptors with specialized functions in immune regulation.
Immunity 2016;44:989e1004.
84. Komura T, Sakai Y, Harada K, Kawaguchi K, Takabatake H,
Kitagawa H, et al. Inflammatory features of pancreatic cancer
highlighted by monocytes/macrophages and CD4þ T cells with
clinical impact. Cancer Sci 2015;106:672e86.
85. Gao M, Lin M, Moffitt RA, Salazar MA, Park J, Vacirca J, et al.
Direct therapeutic targeting of immune checkpoint PD-1 in pancre-
atic cancer. Br J Cancer 2019;120:88e96.
86. Shen T, Zhou L, Shen H, Shi C, Jia S, Ding GP, et al. Prognostic
value of programmed cell death protein 1 expression on CD8þ T
lymphocytes in pancreatic cancer. Sci Rep 2017;7:7848.
87. Diana A, Wang LM, D’Costa Z, Allen P, Azad A, Silva MA, et al.
Prognostic value, localization and correlation of PD-1/PD-L1, CD8
and FOXP3 with the desmoplastic stroma in pancreatic ductal
adenocarcinoma. Oncotarget 2016;7:40992e1004.
88. Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML,
Cheville JC, et al. PD-1 is expressed by tumor-infiltrating immune
cells and is associated with poor outcome for patients with renal cell
carcinoma. Clin Cancer Res 2007;13:1757e61.
89. Waki K, Yamada T, Yoshiyama K, Terazaki Y, Sakamoto S,
Matsueda S, et al. PD-1 expression on peripheral blood T-cell subsets
correlates with prognosis in non-small cell lung cancer. Cancer Sci
2014;105:1229e35.
90. Krönig H, Julia Falchner K, Odendahl M, Brackertz B, Conrad H,
Muck D, et al. PD-1 expression on Melan-A-reactive T cells in-
creases during progression to metastatic disease. Int J Cancer 2012;
130:2327e36.
91. Wang Y, Lin J, Cui J, Han T, Jiao F, Meng Z, et al. Prognostic value
and clinicopathological features of PD-1/PD-L1 expression with
mismatch repair status and desmoplastic stroma in Chinese patients
with pancreatic cancer. Oncotarget 2017;8:9354e65.
92. Tjomsland V, Niklasson L, Sandström P, Borch K, Druid H,
Bratthäll C, et al. The desmoplastic stroma plays an essential role in
the accumulation and modulation of infiltrated immune cells in
pancreatic adenocarcinoma. Clin Dev Immunol 2011;2011:212810.
93. Zou W, Chen L. Inhibitory B7-family molecules in the tumour
microenvironment. Nat Rev Immunol 2008;8:467e77.
94. Wang L, Ma Q, Chen X, Guo K, Li J, Zhang M. Clinical significance
of B7-H1 and B7-1 expressions in pancreatic carcinoma. World J
Surg 2010;34:1059e65.
1094 Seyed Hossein Kiaie et al.95. Daley D, Zambirinis CP, Seifert L, Akkad N, Mohan N, Werba G,
et al. gd T cells support pancreatic oncogenesis by restraining ab T
cell activation. Cell 2016;166:1485e99.
96. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH,
et al. Restoring function in exhausted CD8 T cells during chronic
viral infection. Nature 2006;439:682e7.
97. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N.
Involvement of PD-L1 on tumor cells in the escape from host im-
mune system and tumor immunotherapy by PD-L1 blockade. Proc
Natl Acad Sci U S A 2002;99:12293e7.
98. Song X, Liu J, Lu Y, Jin H, Huang D. Overexpression of B7-H1
correlates with malignant cell proliferation in pancreatic cancer.
Oncol Rep 2014;31:1191e8.
99. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al.
Clinical significance and therapeutic potential of the programmed
death-1 ligand/programmed death-1 pathway in human pancreatic
cancer. Clin Cancer Res 2007;13:2151e7.
100. Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J,
et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macro-
phages and improves response to T-cell checkpoint immunotherapy
in pancreatic cancer models. Cancer Res 2014;74:5057e69.
101. Imai D, Yoshizumi T, Okano S, Uchiyama H, Ikegami T,
Harimoto N, et al. The prognostic impact of programmed cell death
ligand 1 and human leukocyte antigen class I in pancreatic cancer.
Cancer Med 2017;6:1614e26.
102. Geng L, Huang D, Liu J, Qian Y, Deng J, Li D, et al. B7-H1 up-
regulated expression in human pancreatic carcinoma tissue associ-
ates with tumor progression. J Cancer Res Clin Oncol 2008;134:
1021e7.
103. Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, et al.
Clinical significance of programmed death-1 ligand-1 and pro-
grammed death-1 ligand-2 expression in human esophageal cancer.
Clin Cancer Res 2005;11:2947e53.
104. Marin-Acevedo JA, Soyano AE, Dholaria B, Knutson KL, Lou Y.
Cancer immunotherapy beyond immune checkpoint inhibitors. J
Hematol Oncol 2018;11:8.
105. Brunet LR, Hagemann T, Andrew G, Mudan S, Marabelle A. Have
lessons from past failures brought us closer to the success of
immunotherapy in metastatic pancreatic cancer?. Oncoimmunology
2015;5:1112942.
106. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl
J Med 2014;371:1039e49.
107. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of
age. Nature 2011;480:480e9.
108. Solinas C, Gombos A, Latifyan S, Piccart-Gebhart M, Kok M,
Buisseret L. Targeting immune checkpoints in breast cancer: an
update of early results. ESMO Open 2017;2:000255.
109. Jelinek T, Mihalyova J, Kascak M, Duras J, Hajek R. PD-1/PD-L1
inhibitors in haematological malignancies: update 2017. Immunology
2017;152:357e71.
110. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL,
Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy
in untreated melanoma. N Engl J Med 2015;373:23e34.
111. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE,
et al. Nivolumab versus docetaxel in advanced nonsquamous non-
small-cell lung cancer. N Engl J Med 2015;373:1627e39.
112. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ,
Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell
carcinoma. N Engl J Med 2015;373:1803e13.
113. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS,
Balar AV, Necchi A, et al. Atezolizumab in patients with locally
advanced and metastatic urothelial carcinoma who have progressed
following treatment with platinum-based chemotherapy: a single-
arm, multicentre, phase 2 trial. Lancet 2016;387:1909e20.
114. Ferris RL, Blumenschein Jr G, Fayette J, Guigay J, Colevas AD,
Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of
the head and neck. N Engl J Med 2016;375:1856e67.115. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV,
et al. Biologic activity of cytotoxic T lymphocyte-associated antigen
4 antibody blockade in previously vaccinated metastatic melanoma
and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003;100:
4712e7.
116. Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: an
overview of preclinical and translational research. Cancer Immun
2013;13:5.
117. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade
and GM-CSF combination immunotherapy alters the intratumor
balance of effector and regulatory T cells. J Clin Invest 2006;116:
1935e45.
118. Morse MA. Technology evaluation: ipilimumab, medarex/bristol-
myers squibb. Curr Opin Mol Therapeut 2005;7:588e97.
119. Le Mercier I, Lines JL, Noelle RJ. Beyond CTLA-4 and PD-1, the
generation Z of negative checkpoint regulators. Front Immunol 2015;
6:418.
120. Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US,
et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for
locally advanced or metastatic pancreatic adenocarcinoma. J
Immunother 2010;33:828e33.
121. Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, et al. Eval-
uation of ipilimumab in combination with allogeneic pancreatic
tumor cells transfected with a GM-CSF gene in previously treated
pancreatic cancer. J Immunother Appl 2013;36:382e9.
122. Kamath SD, Kalyan A, Kircher S, Nimeiri H, Fought AJ,
Benson III A, et al. Ipilimumab and gemcitabine for advanced
pancreatic cancer: a phase Ib study. Oncology 2019;25:e808e15.
123. Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W. Yeap BY, et al.
Total neoadjuvant therapy with folfirinox in combination with los-
artan followed by chemoradiotherapy for locally advanced pancreatic
cancer: a phase 2 clinical trial. JAMA Oncol 2019;5:1020e7.
124. Chung KY, Gore I, Fong L, Venook A, Beck SB, Dorazio P,
et al. Phase II study of the anti-cytotoxic T-lymphocyte-associ-
ated antigen 4 monoclonal antibody, tremelimumab, in patients
with refractory metastatic colorectal cancer. J Clin Oncol 2010;
28:3485e90.
125. Ribas A, Hanson DC, Noe DA, Millham R, Guyot DJ, Bernstein SH,
et al. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte
associated antigen 4 blocking monoclonal antibody in clinical
development for patients with cancer. Oncology 2007;12:873e83.
126. Aglietta M, Barone C, Sawyer MB, Moore MJ, Miller Jr WH,
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